Literature DB >> 7556228

Prospective study of antigenemia, plasma viremia and lymphocytic viremia in HIV-infected hemophiliacs.

S Melón Garcia1, M de Oña Navarro, C Rodriguez Pinto, M Fernández Urgellés, A Martinez Gutierrez, P de la Iglesia, F J Mendez García.   

Abstract

A total of 186 blood samples from 24 HIV-1 seropositive hemophiliac patients, monitored every four months for 29 months, were investigated for the presence of viral antigen in plasma. In addition, peripheral blood mononuclear cells (PBMC) were cultured for HIV-1, using normal PBMC as a target for replication. Antigenemia was detected in 51% of the patients and from PBMC in 87.5% of the patients. The incidence of HIV isolation in asymptomatic patients (42.8%) was similar to that found in symptomatic patients (51.4%). Patients with opportunistic infections had a higher incidence of lymphocytic viremia (p < 0.05). Plasma viremia was closely associated (p < 0.05) with low CD4+ counts and infection progression. The persistence of antigenemia was also a marker of a poor clinical course. In treated patients, plasma viremia was the marker that better correlated with the clinical course, and it did not appear during the first nine months of therapy. Zidovudine doses of > 500 mg/day significantly lowered the appearance of antigenemia and lymphocytic viremia (p < 0.05).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7556228     DOI: 10.1007/bf02114895

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  28 in total

1.  Plasma viraemia as a marker of viral replication in HIV-infected individuals.

Authors:  S Escaich; J Ritter; P Rougier; D Lepot; J P Lamelin; M Sepetjan; C Trepo
Journal:  AIDS       Date:  1991-10       Impact factor: 4.177

2.  HIV revealed: toward a natural history of the infection.

Authors:  D Baltimore; M B Feinberg
Journal:  N Engl J Med       Date:  1989-12-14       Impact factor: 91.245

3.  Clinical importance of HIV antigen and anti-HIV core markers in persons infected with HIV.

Authors:  P N Lelie; H W Reesink; E Bakker; J G Huisman; J H ten Veen
Journal:  N Engl J Med       Date:  1988-05-05       Impact factor: 91.245

4.  DNA amplification of HIV genome in hemophiliacs and in newborns from seropositive mothers.

Authors:  C de la Salle; M J Baas; D Laustriat; B Guy; E Bordes; M L Wiesel; L Grunebaum; P Lutz; M Partisani; J M Lang
Journal:  Ann Hematol       Date:  1991-05       Impact factor: 3.673

5.  High-level viremia in adults and children infected with human immunodeficiency virus: relation to disease stage and CD4+ lymphocyte levels.

Authors:  M S Saag; M J Crain; W D Decker; S Campbell-Hill; S Robinson; W E Brown; M Leuther; R J Whitley; B H Hahn; G M Shaw
Journal:  J Infect Dis       Date:  1991-07       Impact factor: 5.226

6.  Progression to AIDS in patients with lymphadenopathy or AIDS-related complex: reappraisal of risk and predictive factors.

Authors:  H W Murray; J H Godbold; K B Jurica; R B Roberts
Journal:  Am J Med       Date:  1989-05       Impact factor: 4.965

7.  Predictive markers for the acquired immunodeficiency syndrome (AIDS) in hemophiliacs: persistence of p24 antigen and low T4 cell count.

Authors:  M E Eyster; J O Ballard; M H Gail; J E Drummond; J J Goedert
Journal:  Ann Intern Med       Date:  1989-06-15       Impact factor: 25.391

8.  Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study.

Authors:  T C Meng; M A Fischl; A M Boota; S A Spector; D Bennett; Y Bassiakos; S H Lai; B Wright; D D Richman
Journal:  Ann Intern Med       Date:  1992-01-01       Impact factor: 25.391

9.  The effect of antiviral therapy on the natural history of human immunodeficiency virus infection in a cohort of hemophiliacs.

Authors:  M V Ragni; L A Kingsley; S J Zhou
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1992

10.  Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.

Authors:  P A Volberding; S W Lagakos; M A Koch; C Pettinelli; M W Myers; D K Booth; H H Balfour; R C Reichman; J A Bartlett; M S Hirsch
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.